Jacob Grinfeld1, Jyoti Nangalia1, E Joanna Baxter1, David C Wedge1, Nicos Angelopoulos1, Robert Cantrill1, Anna L Godfrey1, Elli Papaemmanuil1, Gunes Gundem1, Cathy MacLean1, Julia Cook1, Laura O'Neil1, Sarah O'Meara1, Jon W Teague1, Adam P Butler1, Charlie E Massie1, Nicholas Williams1, Francesca L Nice1, Christen L Andersen1, Hans C Hasselbalch1, Paola Guglielmelli1, Mary F McMullin1, Alessandro M Vannucchi1, Claire N Harrison1, Moritz Gerstung1, Anthony R Green1, Peter J Campbell1. 1. From the Wellcome-MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research (J.G., C.E.M., F.L.N., A.R.G., P.J.C.), the Department of Haematology, University of Cambridge (J.G., E.J.B., C.M., J.C., C.E.M., F.L.N., A.R.G.), and the Department of Haematology, Cambridge University Hospitals NHS Foundation Trust (J.G., E.J.B., A.L.G., C.M., J.C., A.R.G.), Cambridge, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (J.N., D.C.W., N.A., E.P., G.G., L.O., S.O., J.W.T., A.P.B., N.W., P.J.C.), and the European Molecular Biology Laboratory, European Bioinformatics Institute (R.C., M.G.), Hinxton, Big Data Institute, University of Oxford, Oxford (D.C.W.), the Department of Haematology, Queen's University Belfast, Belfast (M.F.M.), and the Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.) - all in the United Kingdom; the Center for Molecular Oncology and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York (E.P., G.G.); the Department of Hematology, Zealand University Hospital, Roskilde, and the University of Copenhagen, Copenhagen (C.L.A., H.C.H.); and the Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy (P.G., A.M.V.).
Abstract
BACKGROUND: Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients with myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment. METHODS: We sequenced coding exons from 69 myeloid cancer genes in patients with myeloproliferative neoplasms, comprehensively annotating driver mutations and copy-number changes. We developed a genomic classification for myeloproliferative neoplasms and multistage prognostic models for predicting outcomes in individual patients. Classification and prognostic models were validated in an external cohort. RESULTS: A total of 2035 patients were included in the analysis. A total of 33 genes had driver mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being the sole abnormality in 45% of the patients. The numbers of driver mutations increased with age and advanced disease. Driver mutations, germline polymorphisms, and demographic variables independently predicted whether patients received a diagnosis of essential thrombocythemia as compared with polycythemia vera or a diagnosis of chronic-phase disease as compared with myelofibrosis. We defined eight genomic subgroups that showed distinct clinical phenotypes, including blood counts, risk of leukemic transformation, and event-free survival. Integrating 63 clinical and genomic variables, we created prognostic models capable of generating personally tailored predictions of clinical outcomes in patients with chronic-phase myeloproliferative neoplasms and myelofibrosis. The predicted and observed outcomes correlated well in internal cross-validation of a training cohort and in an independent external cohort. Even within individual categories of existing prognostic schemas, our models substantially improved predictive accuracy. CONCLUSIONS: Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms. Integration of genomic data with clinical variables enabled the personalized predictions of patients' outcomes and may support the treatment of patients with myeloproliferative neoplasms. (Funded by the Wellcome Trust and others.).
BACKGROUND: Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients with myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment. METHODS: We sequenced coding exons from 69 myeloid cancer genes in patients with myeloproliferative neoplasms, comprehensively annotating driver mutations and copy-number changes. We developed a genomic classification for myeloproliferative neoplasms and multistage prognostic models for predicting outcomes in individual patients. Classification and prognostic models were validated in an external cohort. RESULTS: A total of 2035 patients were included in the analysis. A total of 33 genes had driver mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being the sole abnormality in 45% of the patients. The numbers of driver mutations increased with age and advanced disease. Driver mutations, germline polymorphisms, and demographic variables independently predicted whether patients received a diagnosis of essential thrombocythemia as compared with polycythemia vera or a diagnosis of chronic-phase disease as compared with myelofibrosis. We defined eight genomic subgroups that showed distinct clinical phenotypes, including blood counts, risk of leukemic transformation, and event-free survival. Integrating 63 clinical and genomic variables, we created prognostic models capable of generating personally tailored predictions of clinical outcomes in patients with chronic-phase myeloproliferative neoplasms and myelofibrosis. The predicted and observed outcomes correlated well in internal cross-validation of a training cohort and in an independent external cohort. Even within individual categories of existing prognostic schemas, our models substantially improved predictive accuracy. CONCLUSIONS: Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms. Integration of genomic data with clinical variables enabled the personalized predictions of patients' outcomes and may support the treatment of patients with myeloproliferative neoplasms. (Funded by the Wellcome Trust and others.).
Authors: Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: F Passamonti; T Giorgino; B Mora; P Guglielmelli; E Rumi; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R T Silver; G Benevolo; F Albano; D Caramazza; M Merli; D Pietra; R Casalone; G Rotunno; T Barbui; M Cazzola; A M Vannucchi Journal: Leukemia Date: 2017-05-31 Impact factor: 11.528
Authors: Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi Journal: Blood Date: 2008-11-06 Impact factor: 22.113
Authors: A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi Journal: Leukemia Date: 2013-04-26 Impact factor: 11.528
Authors: Lyndal Kearney; David Gonzalez De Castro; Jenny Yeung; Julia Procter; Sharon W Horsley; Minenori Eguchi-Ishimae; Caroline M Bateman; Kristina Anderson; Tracy Chaplin; Bryan D Young; Christine J Harrison; Helena Kempski; Chi Wai E So; Anthony M Ford; Mel Greaves Journal: Blood Date: 2008-10-16 Impact factor: 22.113
Authors: Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green Journal: N Engl J Med Date: 2015-02-12 Impact factor: 91.245
Authors: William Tapper; Amy V Jones; Robert Kralovics; Ashot S Harutyunyan; Katerina Zoi; William Leung; Anna L Godfrey; Paola Guglielmelli; Alison Callaway; Daniel Ward; Paula Aranaz; Helen E White; Katherine Waghorn; Feng Lin; Andrew Chase; E Joanna Baxter; Cathy Maclean; Jyoti Nangalia; Edwin Chen; Paul Evans; Michael Short; Andrew Jack; Louise Wallis; David Oscier; Andrew S Duncombe; Anna Schuh; Adam J Mead; Michael Griffiths; Joanne Ewing; Rosemary E Gale; Susanne Schnittger; Torsten Haferlach; Frank Stegelmann; Konstanze Döhner; Harald Grallert; Konstantin Strauch; Toshiko Tanaka; Stefania Bandinelli; Andreas Giannopoulos; Lisa Pieri; Carmela Mannarelli; Heinz Gisslinger; Giovanni Barosi; Mario Cazzola; Andreas Reiter; Claire Harrison; Peter Campbell; Anthony R Green; Alessandro Vannucchi; Nicholas C P Cross Journal: Nat Commun Date: 2015-04-07 Impact factor: 14.919
Authors: Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld Journal: Blood Adv Date: 2018-12-26
Authors: Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin Journal: Curr Hematol Malig Rep Date: 2019-10 Impact factor: 3.952
Authors: Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes Journal: Leukemia Date: 2019-06-17 Impact factor: 11.528
Authors: Jennifer M O'Sullivan; Angela Hamblin; Christina Yap; Sonia Fox; Rebecca Boucher; Anesh Panchal; Samah Alimam; Helene Dreau; Kieran Howard; Pauline Ware; Nicholas C P Cross; Mary Frances McMullin; Claire N Harrison; Adam J Mead Journal: Blood Date: 2019-12-05 Impact factor: 22.113
Authors: Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha Journal: Leukemia Date: 2021-05-26 Impact factor: 11.528